Eritoran
As of the edition of 20 October 2026, Eritoran is a small molecule: went quiet in 2016; acts on LY96 and TLR4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2016
- Kind
- Small molecule
- Registered trials
- 4, 1 stopped early
- Disease areas
- Infections; Blood and lymph; Cancer; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eisai | Lead sponsor of trials | 2001 to now |